Quantitative elasticity measurements reveal intratumoral changes in response to antiangiogenic therapy - Preliminary results

Proceedings - IEEE Ultrasonics Symposium

Volumn , Issue , 2009, Pages 1443-1446

  Hoyt, Kenneth ^a,c   Warram, Jason M ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antiangiogenic therapy; Bevacizumab; Breast cancer; Tissue elasticity; Ultrasound

Indexed keywords

CELL DEATH; DISEASES; MAMMALS; TUMORS; ULTRASONIC IMAGING; ULTRASONICS;

ANTI-ANGIOGENIC THERAPY; BEVACIZUMAB; BREAST CANCER; CHEMOTHERAPEUTIC AGENTS; ELASTICITY MEASUREMENT; INTERSTITIAL FLUID PRESSURES; TISSUE ELASTICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ELASTICITY;

EID: 77952852065     PISSN: 10510117     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/ULTSYM.2009.5441503     Document Type: Conference Paper

References (15)

1. M. Relf, S. LeJeune, P.A.E. Scott, et al., "Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis," Cancer Res, vol. 57, pp. 963-969, 1997.
2. R.S. Kerbel, "Tumor angiogenesis," N. Engl. J. Med., vol. 358, pp. 2039-2049, 2008.
3. J. Folkman, "How is blood vessel growth regulated in normal and neoplastic tissue?" Cancer Res., vol. 46, pp. 467-473, 1986.
4. R.K. Jain, "Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy," Nature Med., vol. 7, pp. 987-989, 2001.
5. R.K. Jain, "Determinants of tumor blow flow: A review," Cancer Res., vol. 48, pp. 2641-2658, 1988.
6. R.T. Tong, Y. Boucher, S.V. Kozin, et al., "Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors," Cancer Res., vol. 64, pp. 3731-3736, 2004.
7. P.V. Dickson, J.B. Hamner, T.L. Sims, et al., "Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma zenografts results in improved delivery and efficacy of systemically administered chemotherapy," Clin. Cancer Res., vol. 13, pp. 3942-3950, 2007.
8. T. Shih, C. Lindley, "Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies," Clin. Therapeutics, vol. 28, pp. 1779-1802, 2006.
9. M.L. Palmeri, M.H. Wang, J.J. Dahl, et al., "Quantifying hepatic shear modulus in vivo using acoustic radiation force," Ultrasound Med. Biol., vol. 34, pp. 546-558, 2008.
10. M. Tanter, J. Bercoff, A. Athanasiou, et al., "Quantitative assessment of breast lesion viscoelasticity: Initial clinical results using supersonic shear imaging," Ultrasound Med. Biol., vol. 34, pp. 1373-1386, 2008.
11. K. Hoyt, T. Kneezel, B. Castaneda, et al., "Quantitative sonoelastography for the in vivo assessment of skeletal muscle viscoelasticity," Phys. Med. Biol., vol. 53, pp. 4063-4080, 2008.
12. S. Chen, M. Urban, C. Pislaru, et al., "Shearwave dispersion ultrasound vibrometry (SDUV) for measuring tissue elasticity and viscosity," IEEE Trans. Ultrason. Ferroelectr. Freq. Control, vol. 56, pp. 55-62, 2009.
13. R.E. Pollard, A.R. Broumas, E.R. Wisner, et al., "Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats," Ultrasound Med. Biol., vol. 33, pp. 235-245, 2007.
14. M. Selvakumaran, K.S. Yao, M.D. Feldman, et al., "Antitumor effect of the angiogenesis inhibitor bevazicumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis," Biochem. Pharmacol., vol. 75, pp. 627-638, 2008.
15. C. Magnon, A. Galaup, V. Rouffiac, et al., "Dynamic assessment of antiangiongenic therapy by monitoring both tumoral vascularization and tisssue degeneration," Gene Therapy, vol. 14, pp. 108-117, 2007.